Background: Liver transplantation is a challenging procedure that is associated with perioperative morbidity and mortality, so it is justifiable to perform such a procedure in high-volume procedure centers. Organ shortage remains a major issue in Taiwan. Due to the difficulty in establishing a high-volume procedure center, it is important to review the overall outcome of patients undergoing liver transplantation at a small-volume procedure center to determine if performing such a procedure is justified. Methods: Between April 2001 and May 2005, 26 adults underwent deceased donor liver transplantation at Taipei Veterans General Hospital. The overall outcomes were reviewed in terms of 90-day mortality, 1-year and 3-year survival rates. In addition, the patients were divided into a hepatocellular carcinoma (HCC) group (n = 12) and a benign end-stage liver disease (ESLD) group (n = 14). The clinical demographics, 90-day mortality, 1-year and 3-year survival rates were reviewed and compared between the 2 groups. Results: The 90-day mortality was 15.3% in the whole series, 8.3% in the HCC group and 18.7% in the ESLD group. The overall 1-year and 3-year survival rates were 76.9% and 63.5%, respectively, for the whole series. For the 2 groups, the respective 1-year and 3-year survival rates were 83.3% and 71.4% in the HCC group, and 71.4% and 57.1% in the ESLD group. The survival difference was not significant (p = 0.319) between the 2 groups. In the HCC group, the 1-year and 3-year disease-free survival rates were 88.9% and 71.1%, respectively. Conclusion: The survival rates between ESLD and HCC patients undergoing liver transplantation at a small-volume procedure center were comparable. The results of the whole series were not satisfactory, but the results for the HCC group were acceptable. [J Chin Med Assoc 2008;71(4):186-190] 
Introduction
The first human liver transplantation was performed in 1963, but poor initial results kept liver transplantation an experimental surgery for 20 years before it was accepted as a definitive therapeutic modality for endstage liver disease (ESLD). 1 Because of the challenging procedure and high perioperative mortality associated with liver transplantation, it has been suggested that this procedure be done in centers with a high volume of procedures to ensure better patient outcome. 2 Organ shortage has long been a significant problem faced by the transplant society, and because of folk beliefs and religions, organ shortage is generally more severe in Asian countries compared with Western ones. The organ donation rate is about 4.7 per million people per year in Taiwan. 3 This number is far behind that in Spain, a country with an organ donation rate of around 24.1 per million people per year. 4 Therefore, it is difficult to establish a center with a high volume of liver transplants in Taiwan. Under these circumstances, we wanted to review the overall outcome of patients who Liver transplantation at a small-volume procedure center underwent liver transplantations at a small-volume procedure center to determine if it is justifiable to perform liver transplantations at such a center. In addition, subgroup analysis was done to compare the outcome between patients with benign ESLD and patients with hepatocellular carcinoma (HCC).
Methods
The study complied with current ethical guidelines of medical research. Between April 2001 and May 2005, 26 adults underwent deceased donor liver transplantation (DDLT) at Taipei Veterans General Hospital (TVGH). There were 17 males and 9 females. The mean age of these patients was 54.0 ± 10.7 years (range, 24-68 years). Nineteen patients had chronic hepatitis B virus (HBV) infection, 3 had chronic hepatitis C virus (HCV) infection, 2 had Wilson's disease, 1 was an alcoholic, and 1 had cryptogenic liver cirrhosis.
Model of end-stage liver disease (MELD) score was introduced into Taiwan's organ allocation system in 2004. Before 2004, waiting time had been a priority for organ allocation except for urgency. Mean MELD score of the subjects in this study was 14.9 ± 7.6 (range, 6-42). Among the 26 patients, 12 had concomitant HCC preoperatively ( Table 1 ). All of the HCC patients included in this study met the Milan criteria 5 before transplantation.
All patients underwent orthotopic liver transplantation without venous-venous bypass. The immunosuppressant regimen consisted of intraoperative induction of methylprednisolone 1 g and then tapering to oral prednisolone 20 mg on the 7 th postoperative day. Steroid was withdrawn before 6 months after transplantation. The main maintenance immunosuppressant was tacrolimus (Astellas Pharma, Osaka, Japan). The dosage of tacrolimus was 0.025-0.15 mg/kg/day in 2 divided doses. The trough blood level was kept between 2.5 ng/mL and 20 ng/mL.
The patients' clinical demographic data, operative mortality and pathologic results were reviewed. Operative mortality was defined as death within 30 days of transplantation or during the same period of hospitalization. The median follow-up time was 25.3 months (mean, 28.8 ± 10.7 months; range, 1 day to 69.3 months). The patients' overall survival rate was calculated using the Kaplan-Meier method. In addition, patients were further divided into an HCC group (n = 12) and an ESLD group (n = 14). The clinical demographic characteristics, surgical outcomes and survival rates were compared between the 2 groups. Continuous variables were compared using Student's t test, and categorical variables were compared using Fisher's exact test. The difference in survival between the HCC and ESLD groups was calculated using log-rank test.
Results
In this series, 4 patients died within 30 days of transplantation. The causes of mortality in 1 patient each were hemorrhagic shock, small-for-size syndrome, portal vein thrombosis, and intracranial hemorrhage. Operative mortality was 15.3% (4/26). The overall 1-year and 3-year survival rates for the whole series were 76.9% and 63.5%, respectively ( Figure 1 ). 
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The male-to-female ratio in the HCC group was 8 to 4, while it was 9 to 5 in the ESLD group (p = 1.000). The mean age in the HCC group was 58.5 ± 6.6 years, while it was 50.14 ± 12.2 years in the ESLD group (p = 0.039). There was no significant difference in MELD score between the HCC and ESLD groups (13.33 ± 4.9 vs. 16.21 ± 9.2, p = 0.343). Operative mortality was 8.3% (1/12) in the HCC patients and 18.7% (3/16) in the ESLD patients ( Table 2 ). The 1-year survival rates for the HCC patients and ESLD patients were 83.3% and 71.4%, respectively. The 3-year overall survival rates for the HCC patients and ESLD patients were 71.4% and 57.1% (p = 0.319), respectively ( Figure 1 ).
In the HCC group, 1 patient died as a result of post-transplantation intracranial bleeding on postoperative day 9, and 2 died of sepsis, at 5 months and 31 months after transplantation, respectively, without evidence of tumor recurrence (Table 3 ). In the ESLD group, 6 patients died: 3 were due to surgical complications, and 1 each to hemorrhagic shock, portal vein thrombosis and small-for-size syndrome on postoperative days 1, 3 and 7, respectively. The diagnosis of smallfor-size syndrome was made according to the patient's clinical presentations of progressive hyperbilirubinemia without mechanical cause and refractory ascites in the absence of vascular complications within 7 days of liver transplantation. Another 3 patients died of suffocation, sepsis, and suicide, at 7, 13 and 17 months after transplantation, respectively (Table 4 ). Of the 12 HCC patients, 9 had received pre-transplant treatment (1 surgical resection, 1 surgical resection for primary tumor and transarterial embolization for recurrence, 7 locoregional ablative therapies). During the posttransplantation follow-up period, 2 patients were found to have recurrent tumors. One of the 2 patients had intrahepatic recurrence, peritoneal seeding, and lung and spleen metastases at 23 months after transplantation. The other patient had tumor in the liver, lung and brain at 32 months after transplantation. The recurrence rate was 16.7% (2/12). The 1-year disease-free survival rate was 88.8%, and the 3-year disease-free survival rate was 71.1% ( Figure 2 ).
Discussion
Liver transplantation had been an experimental surgery until 1983, 20 years after the first human liver transplant, Liver transplantation at a small-volume procedure center when experts at the Consensus and Development Conference of the National Institute of Health recommended that liver transplantation be a definitive treatment for ESLD. 1 The first successful human liver transplantation in Asia was performed in Taiwan by Chen et al in 1984. 6 Their successful operation influenced the development of liver transplantation not only in Taiwan but also in other Asian countries. Soon after the first liver transplantation in Asia, the first liver transplantation at TVGH was performed, on In spite of an increased number of organ donations in Taiwan during the past decade, there were only 73 liver grafts available from deceased donors in 2005. 3 Under such circumstances, it is difficult to establish a high-volume procedure center in Taiwan. Hence, it is necessary to review the results of a small-volume procedure center to see if it is justifiable to perform liver transplantation.
According to the report of Edwards et al, 2 the 90-day mortality rate at low-volume centers was 20.9%, while it was 14.1% at high-volume centers (> 20 procedures/year). The 1-year mortality rate at lowvolume centers ranged from 25.9% to 29.9%, and from 20.0% to 25.1% at high-volume centers, according to the different time periods. In our series, the 90-day mortality rate was 15.3%, and the 1-year mortality rate was 23.1%. These results are comparable to those of highvolume centers reported by Edwards et al. 2 It is generally accepted that the 1-year survival rate is 80% and the 3-year survival rate is 75% for ESLD patients undergoing liver transplantation. Our series showed that ESLD patients undergoing liver transplantation achieved a 1-year survival rate of 71.4% and a 3-year survival rate of 57.1%. These results are not satisfactory. The reason for the unsatisfactory outcome was mainly due to 3 of the 6 cases of mortality occurring within 30 days after transplantation. The mean MELD score in our patients was 14.9 ± 7.6, which means that most of our patients were not critically ill. Refinement of perioperative care and surgical techniques should decrease surgical mortality and improve patient survival.
Liver transplantation is justified for patients with liver malignancy only when the outcome after transplantation is comparable to that of patients with ESLD, especially in a country with organ shortages. The prognosis of patients with HCC undergoing liver transplantation in the initial series was disappointing. Even in the early 1990s, the 5-year survival rate was 15-48%. [7] [8] [9] [10] The tumor recurrence rate was up to 54%. 9 The poor outcome was mainly due to unrestrictive patient selection criteria. In the late 1990s, the survival rate of HCC patients undergoing liver transplantation improved greatly. The most notable result was from the Milan group. In 1996, Mazzaferro et al 5 demonstrated that HCC patients with a single tumor no larger than 5 cm, or with no more than 3 tumors with each tumor being no larger than 3 cm, could achieve a 1-year survival rate of 90% and a 3-year survival rate of 76%. The overall recurrence rate was 8%, and the 4-year disease-free survival rate was 83%. These selection criteria were called the Milan criteria. With restrictive patient selection criteria, these satisfactory outcomes were reproducible in other later series. [11] [12] [13] In Taiwan, we follow the Milan criteria for patients with HCC undergoing DDLT. In this series, 12 patients with HCC underwent liver transplantation. Our results showed that the 1-year and 3-year overall survival rates were 83.3% and 71.4%, respectively; 1-year and 3-year disease-free survival rates were 88.9% and 71.1%, respectively. The figures were better than those for our patients with ESLD, although the difference was not statistically significant (p = 0.319). The outcome was also comparable to results from other larger series. 5, [11] [12] [13] The preliminary results of this whole series were not satisfactory but they were acceptable, especially for the HCC group. The results indicate that liver transplantation at a center with a small volume of procedures in Taiwan is justifiable, but there remains much room for further improvement.
